Bachem Confirms Growth and Expects a Strong Second Half 2026

Rhea-AI Summary

Bachem (OTC: BCHMY; SIX: BANB) reported first-half 2026 sales of CHF 326.4 million, up 4.3% year-on-year (+7.3% in local currencies). EBITDA declined 9.0% to CHF 82.8 million, with margin falling to 25.4%, mainly due to expected ramp-up costs for the new large-scale facility Building K.

Net income edged up to CHF 50.3 million (+0.3%). Clinical CMC Development sales grew 35.4% to CHF 167.5 million, while Commercial API sales fell 21.0% to CHF 133.0 million. Bachem invested CHF 148.4 million in capacity in H1 and plans CHF 350–400 million in 2026, plus a >CHF 500 million Sisslerfeld site. The company guides for 2026 local-currency sales growth of 35–40% and an EBITDA margin in the low thirties, and appointed Boris Corpataux as Chief Commercial Officer effective August 1, 2026.

Positive

• Group sales CHF 326.4m, +4.3% YoY (+7.3% LC)
• CMC Development sales CHF 167.5m, +35.4% YoY (+39.5% LC)
• Research & Specialties sales CHF 25.9m, +24.4% YoY (+30.5% LC)
• Net income CHF 50.3m, +0.3% YoY, 15.4% margin
• 2026 guidance 35–40% sales growth in local currencies
• 2026 EBITDA margin outlook in low thirties (local currencies)
• Capacity expansion capex CHF 148.4m H1 2026; CHF 350–400m planned 2026
• Sisslerfeld project first phase via strategic collaboration, >CHF 500m investment
• Building K in commercial operation, supporting long-term high-volume growth

Negative

• EBITDA CHF 82.8m, -9.0% YoY; margin 25.4% vs. 29.1%
• EBIT CHF 54.1m, -19.1% YoY; margin 16.6% vs. 21.4%
• Commercial API sales CHF 133.0m, -21.0% YoY (-19.3% LC)
• Profitability pressure from Building K ramp-up costs
• High 2026 investment plan CHF 350–400m plus >CHF 500m for Sisslerfeld site

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Bubendorf, Switzerland--(Newsfile Corp. - July 30, 2026) - Ad hoc announcement pursuant to Art. 53 LR

Media Release

• Group sales grew to CHF 326.4 million (+4.3% compared to the prior-year period, +7.3% in local currencies).
• EBITDA amounted to CHF 82.8 million (-9.0% compared to the prior-year period, -4.2% in local currencies) with a margin of 25.4% (prior-year period: 29.1%).
• Ramp-up costs for Building K affected the operating result as expected.
• Bachem appoints Boris Corpataux as Chief Commercial Officer to the Corporate Executive Committee.

Outlook

• For 2026, Bachem expects sales growth between 35% and 40% in local currencies.
• Bachem confirms its outlook for an EBITDA margin in 2026 in local currencies in the low thirties.
• The company plans to make investments between CHF 350 million and CHF 400 million in 2026.

 

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10552/307263_figure1.png

Anne-Kathrin Stoller, CEO of Bachem, on the results for the first half of the year:

«We have made a successful start to the year and were able to further increase our sales in the first half. As expected, the ramp-up costs for Building K has had an impact on our profitability. However, with the ongoing ramp up of this facility – our largest to date for high-volume production – and further operational improvements, we expect a significantly positive trend in the second half.»

Group results

The Bachem Group (SIX: BANB) achieved sales of CHF 326.4 million in the first half of 2026
(+4.3% compared to the prior-year period: CHF 313.0 million). In local currencies (LC), sales increased by 7.3%.

Operating income before depreciation and amortization (EBITDA) amounted to CHF 82.8 million (-9.0%, -4.2% in LC), and operating income (EBIT) was CHF 54.1 million (-19.1%, -13.1% in LC).

As a result, the EBITDA margin was 25.4% (first half of 2025: 29.1%) and the EBIT margin was 16.6% (first half of 2025: 21.4%). In local currencies, the EBITDA margin was 25.9% and the EBIT margin was 17.3%.

Net income increased to CHF 50.3 million (+0.3%) with a margin of 15.4% (first half of 2025: 16.0%) despite the expected ramp-up costs.

Sales by product category

In the clinical drug development category (CMC Development), sales increased to CHF 167.5 million (first half of 2025: CHF 123.7 million, +35.4%, in LC: +39.5%).

The Commercial API category achieved sales of CHF 133.0 million (first half of 2025: CHF 168.4 million, -21.0%, in LC: -19.3%).

The research chemicals and specialties business (Research & Specialties) delivered CHF 25.9 million (first half of 2025: CHF 20.8 million, +24.4%, in LC: +30.5%).

Substantial capacity expansion 

Bachem continued to pursue its comprehensive investment program to expand production capacity in the first half of 2026. A total of CHF 148.4 million was invested with significant volumes to be invested in the second half of the year. In addition to expansion, Bachem is also continuously optimizing the utilization of existing buildings and facilities through operational improvements.

Building K, constructed for large-scale production, was successfully put into operation in 2026. Commercial GMP products are already being manufactured here. The facility is being gradually expanded to provide additional capacity. The successful ramp-up of commercial production is a key component of Bachem’s long-term growth strategy.

Bachem is planning for a large-volume manufacturing site in Sisslerfeld (Eiken, Switzerland). The first expansion phase of this project will be realized through a strategic collaboration, with an investment volume of more than CHF 500 million. Production at the new site is expected to start by 2030.

Bachem continues to invest in its entire network of sites, focusing on site-specific core competencies. Also in the US, high-volume capacity is being expanded. At the same time, Bachem is also focusing on promising small-volume clinical projects in the US, while investments in Western Switzerland are aimed at securing the supply of key precursors.

Bachem appoints Boris Corpataux to the Corporate Executive Committee

Bachem has appointed Boris Corpataux as Chief Commercial Officer effective August 1, 2026. In this role, he will become a member of the Corporate Executive Committee. Boris Corpataux brings extensive experience in sales and in working with strategic partners. He has been with the company for more than twenty years and has a deep understanding of Bachem’s markets, business relationships, and long-term partnerships. With his appointment, Bachem ensures continuity in customer relationships and in its market-related priorities.

Outlook

For 2026, Bachem expects sales growth in local currencies between 35% and 40%. The EBITDA margin in local currencies should be in the low thirties. The company plans to invest between CHF 350 million and CHF 400 million in 2026.

The Half-Year Report 2026 and the presentation for the analyst- and media call are available on the website under the following link:
https://www.bachem.com/about-bachem/investor-hub/reports-and-presentations/

Financial Calendar

November 26, 2026   Capital Markets Day

March 4, 2027            Publication of Annual Report 2026

April 28, 2027             Annual General Meeting (financial year 2026)

July 29, 2027              Publication of Half-Year Report 2027

About Bachem

Bachem is a leading, innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides. The company, which has over 50 years of experience and expertise, provides products for research, clinical development, and commercial applications to pharmaceutical and biotechnology companies worldwide and offers a comprehensive range of services. Bachem operates internationally with its headquarters in Switzerland and production sites in Europe and the US. The company is listed on the SIX Swiss Exchange. For further information, see www.bachem.com.

For more information
Media Patrick Barth Head Group Communications Tel.: +41 58 595 4522 Email: media@bachem.com	Investors Barbora Blaha Head Investor Relations Tel.: +41 58 595 0573 Email: ir@bachem.com

 

This publication may contain specific forward-looking statements, e.g., statements including terms like "believe", "assume", "expect", "forecast", "project", "may", "could", "might", "will" or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of Bachem Holding AG and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties, readers should not rely on forward-looking statements. Bachem Holding AG assumes no responsibility to up-date forward-looking statements or to adapt them to future events or developments.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/307263

FAQ

How did Bachem (BCHMY) perform financially in the first half of 2026?

Bachem reported first-half 2026 sales of CHF 326.4 million, up 4.3% year-on-year. According to Bachem, EBITDA fell 9.0% to CHF 82.8 million, while net income inched up 0.3% to CHF 50.3 million, despite ramp-up costs.

What 2026 guidance did Bachem (BCHMY) provide for sales growth and EBITDA margin?

Bachem expects 35–40% sales growth in local currencies for 2026. According to Bachem, the 2026 EBITDA margin in local currencies is forecast to be in the low thirties, supported by Building K’s ramp-up and ongoing operational improvements across its network.

How are Bachem’s different product categories performing in 2026?

Bachem’s CMC Development sales rose 35.4% to CHF 167.5 million, while Commercial API sales declined 21.0% to CHF 133.0 million. According to Bachem, Research & Specialties increased 24.4% to CHF 25.9 million, highlighting strong growth in development and specialty segments.

What major capacity expansion plans has Bachem (BCHMY) announced up to 2030?

Bachem invested CHF 148.4 million in H1 2026 and plans CHF 350–400 million in 2026. According to Bachem, the first phase of a Sisslerfeld manufacturing site, realized via strategic collaboration, will exceed CHF 500 million, with production expected to start by 2030.

What is Building K and how does it impact Bachem’s 2026 results?

Building K is Bachem’s large-scale production facility, now in commercial GMP operation. According to Bachem, expected ramp-up costs weighed on 2026 profitability, but the ongoing ramp-up and added capacity are described as key elements of the company’s long-term growth strategy.

Who is Bachem’s new Chief Commercial Officer and when does he start?

Bachem appointed Boris Corpataux as Chief Commercial Officer effective August 1, 2026. According to Bachem, he joins the Corporate Executive Committee and brings over twenty years’ experience at the company, supporting continuity in customer relationships and strategic market priorities.

How much will Bachem invest in 2026, and what is the focus of this spending?

Bachem plans to invest CHF 350–400 million in 2026, focused on expanding capacity and optimizing sites. According to Bachem, funds target large-volume facilities, including Building K and the planned Sisslerfeld site, and strengthening US and Western Switzerland capabilities.